X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
143
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 20.70 | 0.23% |
| CAC 40 | 7,985.53 | 70.17 | 0.89% |
| DAX 40 | 23,612.32 | 356.31 | -1.49% |
| Dow JONES (US) | 47,857.06 | 116.26 | 0.24% |
| FTSE 100 | 10,320.10 | 92.14 | -0.88% |
| HKSE | 25,898.76 | 61.14 | -0.24% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 194.30 | 1.48% |
| S&P 500 | 6,807.19 | 11.20 | 0.16% |
| S&P/ASX 200 | 8,743.50 | 19.40 | 0.22% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |